Motley Fool Asset Management LLC Increases Position in Moderna, Inc. (NASDAQ:MRNA)

Motley Fool Asset Management LLC lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,486 shares of the company’s stock after purchasing an additional 684 shares during the period. Motley Fool Asset Management LLC’s holdings in Moderna were worth $1,043,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. First Pacific Financial purchased a new stake in Moderna during the 3rd quarter worth about $27,000. Arlington Trust Co LLC boosted its holdings in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC increased its stake in Moderna by 54.1% in the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after purchasing an additional 180 shares during the last quarter. Archer Investment Corp increased its stake in Moderna by 71.2% in the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after purchasing an additional 222 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its holdings in Moderna by 44.9% during the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after purchasing an additional 175 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the subject of several research analyst reports. HSBC restated a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Moderna in a report on Thursday, March 28th. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Finally, Canaccord Genuity Group lifted their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $126.49.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the sale, the director now owns 2,056,931 shares in the company, valued at $212,645,526.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The disclosure for this sale can be found here. Insiders have sold a total of 109,954 shares of company stock valued at $11,533,976 in the last ninety days. 15.70% of the stock is currently owned by company insiders.

Moderna Stock Performance

MRNA traded up $1.79 during trading on Friday, reaching $107.97. The company’s stock had a trading volume of 2,245,667 shares, compared to its average volume of 4,077,747. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The company’s fifty day moving average price is $102.15 and its 200-day moving average price is $93.73. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The company has a market capitalization of $41.34 billion, a price-to-earnings ratio of -8.70 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.61 earnings per share. On average, equities analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.